Compare Mesoblast Limited (MESO) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs New York Times Co — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while New York Times Co trades at $74.77 (market cap $12.29B). The key difference: New York Times Co is far larger — about 5.7× Mesoblast Limited's market cap, and New York Times Co pays a 1.21% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | NYT | |
|---|---|---|
Market Cap | $2.17B | $12.29B |
Sector | Technology | Media |
52-Week High | $20.96 | $85.86 |
52-Week Low | $12.88 | $51.43 |
Enterprise Value | $2.17B | $11.68B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
The New York Times Company (NYSE: NYT) trades at $75.44, down 0.65% today, with a bullish technical signal and strong fundamentals. Revenue grew to $2.82B in 2025, with net income reaching $344M and profit margins expanding to 12.17%. Recent quarters show consistent earnings beats, and the company announced a $0.23 dividend payable July 23, 2026. Positive cash flow from operations of $584M supports financial health, while analyst consensus price target is $78.00.
Outlook remains positive with steady revenue growth and profitability, though high valuation multiples (P/E 32.59) pose risks. Key catalysts include Q2 2026 earnings on August 5, 2026, and ongoing digital subscription growth. Risks involve regulatory pressures from recent subpoenas to journalists and competitive media landscape. Institutional sentiment is mixed with 29% buy ratings, suggesting cautious optimism for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
